-+ 0.00%
-+ 0.00%
-+ 0.00%
Lexicon's Sotagliflozin Reduces Clot Formation in Small Healthy-Volunteer Study
Share
Listen to the news
Lexicon's Sotagliflozin Reduces Clot Formation in Small Healthy-Volunteer Study
  • Lexicon Pharmaceuticals presented two sotagliflozin studies at the 2026 American Heart Association Scientific Sessions, highlighting effects on clot formation and heart muscle.
  • A randomized crossover trial in 15 healthy adults found significantly reduced clot formation with sotagliflozin; empagliflozin reductions were not statistically significant.
  • Human heart tissue research showed sotagliflozin directly reduced heart muscle workload, with greater potency than empagliflozin under conditions mimicking hypertrophic cardiomyopathy.
  • The ongoing Phase 3 SONATA-HCM trial targets symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy, with topline results expected in first-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090830PRIMZONEFULLFEED9872642) on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending